Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 501–600 of 1,017
Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R., de Bruin, E. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7336 · Cited by 121
Mutational spectrum of adult T-ALL
Neumann, M., Vosberg, S., Schlee, C., Heesch, S., Schwartz, S., Gökbuget, N., Hoelzer, D. F., Graf, A., Krebs, S., Bartram, I., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2218 · Cited by 135
Yang, Y., Yang, H. H., Hu, Y., Watson, P. H., Liu, H., Geiger, T. R., Anver, M. R., Haines, D. C., Martin, P., Green, J. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15695 · Cited by 121
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Colli, L. M., Machiela, M. J., Zhang, H., Myers, T. A., Jessop, L., Delattre, O., Yu, K. F., & Chanock, S. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3338 · Cited by 128
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000038508 · Cited by 172
“In a comprehensive meta-analysis of cancer genome sequencing studies, PIK3CA and PTEN were reported to be the second and third most frequently mutated genes in human cancers, [98] with a PIK3CA mutation rate of 31% in HER2-positive breast cancer.”
BackgroundThe Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Mishima, Y., Paiva, B., Shi, J., Park, J., Manier, S., Takagi, S., Massoud, M., Perilla-Glen, A., Aljawai, Y., Huynh, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.025 · Cited by 121
“The development of “liquid biopsies” presents new opportunities for non-invasive monitoring of clonal heterogeneity (Lawrence et al., 2014).”
BackgroundGenomic analysis of liver cancer unveils novel driver genes and distinct prognostic features
Li, X., Xu, W., Kang, W., Wong, S. H., Wang, M., Zhou, Y., Fang, X., Zhang, X., Yang, H., Wong, C. H., et al. (2018) · Theranostics · doi:10.7150/thno.22010 · Cited by 128
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
“Discovered in the late 1980s, the family of lipid kinases named phosphoinositide 3-kinase (PI3K) and the correlated PI3K/AKT signalling pathway have been shown to play a pivotal role in different oncogenic processes including cell survival, metabolism and metastasis [1].”
BackgroundEvolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer
Dasgupta, B., & Chhipa, R. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.007 · Cited by 118
Li, X., Wu, W. K. K., Xing, R., Wong, S. H., Liu, Y., Fang, X., Zhang, Y., Wang, M., Wang, J., Li, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2443 · Cited by 132
The Damaging Effect of Passenger Mutations on Cancer Progression
McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 120
Luo, P., Ding, Y., Lei, X., & Wu, F.-X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00013 · Cited by 107
“Tokheim et al. propose a random forest algorithm (known as 20/20+) and compare it with seven classical driver gene prediction algorithms [ActiveDriver (Reimand and Bader, 2013), MuSiC (Dees et al., 2012), MutsigCV (Lawrence et al., 2014), OncodriveCLUST (Tamborero et al., 2013), OncodriveFM (Gonzalez-Perez and Lopez-B…”
MethodResultVariegated RHOA mutations in adult T-cell leukemia/lymphoma
Nagata, Y., Kontani, K., Enami, T., Kataoka, K., Ishii, R., Totoki, Y., Kataoka, T. R., Hirata, M., Aoki, K., Nakano, K., et al. (2016) · Blood · doi:10.1182/blood-2015-06-644948 · Cited by 118
Ibrahimpašić, T., Xu, B., Landa, I., Doğan, S., Middha, S., Seshan, V., Deraje, S., Carlson, D. L., Migliacci, J. C., Knauf, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1183 · Cited by 124
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis
Schrock, M. S., Stromberg, B. R., Scarberry, L., & Summers, M. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.001 · Cited by 127
The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression
Zou, T., & Lin, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115754 · Cited by 133
Elvers, I., Turner-Maier, J., Swofford, R., Koltookian, M., Johnson, J., Stewart, C., Zhang, C.-Z., Schumacher, S. E., Beroukhim, R., Rosenberg, M. W., et al. (2015) · Genome Research · doi:10.1101/gr.194449.115 · Cited by 133
“FBXW7 has been shown to be recurrently mutated at two amino acid positions in human cancers (Lawrence et al. 2014).”
BackgroundResultInfluentialSelf-citationSpeicher, M. R., & Pantel, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2897 · Cited by 127
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains
Miller, M. L., Reznik, E., Gauthier, N. P., Aksoy, B. A., Korkut, A., Gao, J., Ciriello, G., Schultz, N., & Sander, C. (2015) · Cell Systems · doi:10.1016/j.cels.2015.08.014 · Cited by 118
“One of these widely applied algorithms, MutSigCV, compares the gene-specific mutation burden to a background model using silent mutations in the gene and gene neighborhood as well as contextual information (DNA replication timing and general level of transcriptional activity) to estimate the probability that the gene…”
InfluentialChang, W., Brohl, A. S., Patidar, R., Sindiri, S., Shern, J. F., Wei, J. S., Song, Y. K., Yohe, M. E., Gryder, B., Zhang, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2717 · Cited by 117
Pitt, J. J., Riester, M., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Oluwasola, O., Veloso, A., Labrot, E., Wang, S., Odetunde, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06616-0 · Cited by 161
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
Pan, R., Chung, W., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Chung, W. (2018) · Journal of Immunology Research · doi:10.1155/2018/4325874 · Cited by 132
Megquier, K., Turner-Maier, J., Swofford, R., Kim, J. H., Sarver, A. L., Wang, C., Sakthikumar, S., Johnson, J., Koltookian, M., Lewellen, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0221 · Cited by 128
The role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 124
Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases
Buljan, M., Ciuffa, R., van Drogen, A., Vichalkovski, A., Mehnert, M., Rosenberger, G., Lee, S., Varjosalo, M., Pernas, L. E., Spegg, V., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.001 · Cited by 117
“, included in the CGC) or were reported to be mutated at a significant frequency in cancer patients (Davoli et al., 2013; Futreal et al., 2004; Lawrence et al., 2014; Vogelstein et al., 2013).”
BackgroundDirectly targeting transcriptional dysregulation in cancer
Gonda, T. J., & Ramsay, R. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4018 · Cited by 124
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 131
“In particular, MED12 mutations have been reported with increasing frequency in a variety of tumors, consistent with its recent identification through large scale genomic analyses as one of only several hundred so-called ‘‘cancer driver genes’’ (Lawrence et al., 2014; Vogelstein et al., 2013).”
Systematic discovery of complex insertions and deletions in human cancers
Ye, K., Wang, J., Jayasinghe, R., Lameijer, E.-W., McMichael, J. F., Ning, J., McLellan, M. D., Xie, M., Cao, S., Yellapantula, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4002 · Cited by 117
“…genes originated from recent publications, including 294 genes from Frampton et al. 24 , 125 genes from Kandoth et al. 26 , 212 genes from Lawrence et al. 27 , 194 genes from Pritchard et al. 28 , 124 genes from Vogelstein et al. 31 , 48 genes from Rahman et al., 29 and 48 from Kanchi et al. 25 .”
Embryonic transcription is controlled by maternally defined chromatin state
Hontelez, S., van Kruijsbergen, I., Georgiou, G., van Heeringen, S. J., Bogdanovic, O., Lister, R., & Veenstra, G. J. C. (2015) · Nature Communications · doi:10.1038/ncomms10148 · Cited by 117
“Key proteins of the molecular machinery involved in DNA methylation (Dnmt3a, Tet2), H3K4me3 (Mll1-4, Kdm5b/c), H3K27me3 (Ezh2, Eed, Kdm6a/b) and enhancer histone acetylation (p300) are not only highly conserved between species but also frequently mutated in cancer 49–51 .”
APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability
Sansregret, L., Patterson, J. O., Dewhurst, S. M., López‐García, C., Koch, A., McGranahan, N., Chao, W. C. H., Barry, D. J., Rowan, A., Instrell, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0645 · Cited by 125
The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma
Mroczek, S., Chlebowska, J., Kuliński, T. M., Gewartowska, O., Gruchota, J., Cysewski, D., Liudkovska, V., Borsuk, E., Nowis, D., & Dziembowski, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00578-5 · Cited by 117
Recent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 125
The Case for Proteomics and Phospho‐Proteomics in Personalized Cancer Medicine
Doll, S., Gnad, F., & Mann, M. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800113 · Cited by 117
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 115
Self-citationMolecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 137
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast
Piscuoglio, S., Ng, C. K. Y., Geyer, F. C., Burke, K. A., Cowell, C. F., Martelotto, L. G., Natrajan, R., Popova, T. G., Maher, C. A., Lim, R. S., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0048-0 · Cited by 118
Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis
El-Naggar, A. M., Somasekharan, S. P., Wang, Y., Cheng, H., Negri, G. L., Pan, M., Wang, X. Q., Delaidelli, A., Rafn, B., Cran, J., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948375 · Cited by 118
“NRF2-activating or KEAP1-inactivating mutations [65], or oncogene-mediated transcriptional induction of NRF2 [7], contribute to NRF2 activation in diverse tumor types.”
Nuclear receptors in cancer — uncovering new and evolving roles through genomic analysis
Dhiman, V. K., Bolt, M. J., & White, K. P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.102 · Cited by 121
A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer
Saito, T., Niida, A., Uchi, R., Hirata, H., Komatsu, H., Sakimura, S., Hayashi, S., Nambara, S., Kuroda, Y., Ito, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05226-0 · Cited by 119
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Mattos‐Arruda, L. D., Sammut, S., Ross, E. M., Bashford-Rogers, R. J. M., Greenstein, E., Markus, H., Morganella, S., Teng, Y. H. F., Maruvka, Y. E., Pereira, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.098 · Cited by 119
Self-citationConcepcion, C. P., Ma, S., LaFave, L. M., Bhutkar, A. J., Liu, M., DeAngelo, L. P., Kim, J. Y., Priore, I. S. D., Schoenfeld, A. J., Miller, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0248 · Cited by 141
Pan-cancer analysis of whole genomes
Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O., & Stein, L. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/162784 · Cited by 114
Self-citationPrecision cancer mouse models through genome editing with CRISPR-Cas9
Mou, H., Kennedy, Z., Anderson, D. G., Yin, H., & Xue, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0178-7 · Cited by 113
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 132
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Ng, C. K. Y., Bidard, F., Piscuoglio, S., Geyer, F. C., Lim, R. S., de Bruijn, I., Shen, R., Pareja, F. G., Berman, S., Wang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3115 · Cited by 121
Genomic determinants of chronic myelomonocytic leukemia
Patel, B. J., Przychodzen, B. P., Thota, S., Radivoyevitch, T., Visconte, V., Kuzmanovic, T., Clemente, M. J., Hirsch, C. M., Morawski, A. R., Souaid, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.164 · Cited by 118
Pathway and network analysis of more than 2500 whole cancer genomes
Reyna, M. A., Haan, D., Paczkowska, M., Verbeke, L. P. C., Vazquez, M., Kahraman, A., Pulido-Tamayo, S., Barenboim, J., Wadi, L., Dhingra, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14367-0 · Cited by 112
Self-citationPan-cancer proteogenomics connects oncogenic drivers to functional states
Li, Y., Porta‐Pardo, E., Tokheim, C. J., Bailey, M. H., Yaron, T. M., Stathias, V., Geffen, Y., Imbach, K. J., Cao, S., Anand, S. K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.014 · Cited by 134
Self-citationAmino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 112
Zapata, L., Pich, O., Serrano, L., Kondrashov, F. A., Ossowski, S., & Schaefer, M. H. (2018) · Genome biology · doi:10.1186/s13059-018-1434-0 · Cited by 132
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Deng, S., Leong, H. C., Datta, A., Gopal, V., Kumar, A. P., & Yap, C. T. (2022) · Cancers · doi:10.3390/cancers14071652 · Cited by 134
Enhancer deregulation in cancer and other diseases
Herz, H. (2016) · BioEssays · doi:10.1002/bies.201600106 · Cited by 111
Allen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 118
Li, X., Wang, M., Yang, M., Dai, H., Zhang, B., Wang, W., Chu, X. L., Wang, X., Zheng, H., Niu, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy011 · Cited by 124
Metabolic interplays between the tumour and the host shape the tumour macroenvironment
Altea‐Manzano, P., Decker-Farrell, A. R., Janowitz, T., & Erez, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00786-4 · Cited by 150
“For example, PI3K, as part of the PI3K–AKT–mTOR pathway, stimulates cell proliferation in different tumours 73,74 , and PI3K inhibitors have been clinically approved to treat several cancer types 75–77 .”
McGrath, J. P., Williamson, K. E., Balasubramanian, S., Odate, S., Arora, S., Hatton, C., Edwards, T. M., O’Brien, T., Magnuson, S. R., Stokoe, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2333 · Cited by 117
The mechanism of PI3Kα activation at the atomic level
Zhang, M., Jang, H., & Nussinov, R. (2019) · Chemical Science · doi:10.1039/c8sc04498h · Cited by 111
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Newell, F., Johansson, P. A., Wilmott, J. S., Nones, K., Lakis, V., Pritchard, A. L., Lo, S., Rawson, R. V., Kazakoff, S. H., Colebatch, A. J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0603 · Cited by 149
Protein conformational ensembles in function: roles and mechanisms
Nussinov, R., Liu, Y., Zhang, W., & Jang, H. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00114h · Cited by 136
Crosstalk between Nrf2 and Notch signaling
Wakabayashi, N., Chartoumpekis, D. V., & Kensler, T. W. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.017 · Cited by 112
A Scalable Genome-Editing-Based Approach for Mapping Multiprotein Complexes in Human Cells
Dalvai, M., Loehr, J., Jacquet, K., Huard, C., Lopez‐Roques, C., Herst, P. M., Côté, J., & Doyon, Y. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.009 · Cited by 123
“Besides, the growing list of cancerrelated genes often comprises uncharacterized proteins for which focused proteomic studies could help uncover function (Lawrence et al., 2014; Vogelstein et al., 2013).”
Wu, K., Zhang, X., Li, F., Xiao, D., Hou, Y., Zhu, S., Liu, D., Ye, X., Ye, M., Yang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms10131 · Cited by 115
Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers
Zhu, B., Song, N., Shen, R., Arora, A., Machiela, M. J., Song, L., Landi, M. T., Ghosh, D., Chatterjee, N., Baladandayuthapani, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17031-8 · Cited by 109
Alqahtani, A., Ayesh, H., & Halawani, H. (2019) · Cancers · doi:10.3390/cancers12010093 · Cited by 121
Accelerating the understanding of cancer biology through the lens of genomics
Wang, D., Liu, B., & Zhang, Z. (2023) · Cell · doi:10.1016/j.cell.2023.02.015 · Cited by 126
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Cancer whole-genome sequencing: present and future
Nakagawa, H., Wardell, C. P., Furuta, M., Taniguchi, H., & Fujimoto, A. (2015) · Oncogene · doi:10.1038/onc.2015.90 · Cited by 121
Mutations and Modeling of the Chromatin Remodeler CHD8 Define an Emerging Autism Etiology
Barnard, R. A., Pomaville, M. B., & O'Roak, B. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00477 · Cited by 107
“…in both midfetal brain and hNSCs were highly enriched for candidate ASD risk genes from two gene sets as defined by and Liu et al., “Liu set” (p < 0.0001) and the “Willsey set” (p < 0.0001; Willsey et al., 2013; Liu et al., 2014), while genes with binding sites only in hNSCs were not enriched.”
BackgroundInfluentialComprehensive nucleosome interactome screen establishes fundamental principles of nucleosome binding
Skrajna, A., Goldfarb, D., Kedziora, K. M., Cousins, E. M., Grant, G. D., Spangler, C. J., Barbour, E. H., Yan, X., Hathaway, N. A., Brown, N. G., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa544 · Cited by 107
Systematic analysis of somatic mutations impacting gene expression in 12 tumour types
Ding, J., McConechy, M. K., Horlings, H. M., Ha, G., Chan, F. C., Funnell, T., Mullaly, S. C., Reimand, J., Bashashati, A., Bader, G. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9554 · Cited by 114
The challenges of tumor genetic diversity
Mroz, E. A., & Rocco, J. W. (2016) · Cancer · doi:10.1002/cncr.30430 · Cited by 120
Srivastava, A., & Creek, D. J. (2018) · PROTEOMICS · doi:10.1002/pmic.201700448 · Cited by 117
Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques
Petrovic, J., Zhou, Y., Fasolino, M., Goldman, N., Schwartz, G. W., Mumbach, M. R., Nguyen, S. C., Rome, K., Sela, Y., Zapataro, Z., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.006 · Cited by 110
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Kamran, S. C., Lennerz, J. K., Margolis, C. A., Liu, D., Reardon, B. M., Wankowicz, S. A. M., Seventer, E. E. V., Tracy, A. A., Wo, J. Y.-L., Carter, S. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0908 · Cited by 116
A lncRNA-SWI/SNF complex crosstalk controls transcriptional activation at specific promoter regions
Grossi, E., Raimondi, I., Goñi, E., González, J., Marchese, F. P., Chapaprieta, V., Martín-Subero, J. I., Guo, S., & Huarte, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14623-3 · Cited by 128
Park, J., Daniels, J., Wartewig, T., Ringbloom, K. G., Martínez‐Escala, M. E., Choi, S., Thomas, J. J., Doukas, P. G., Yang, J., Snowden, C. K., et al. (2021) · Blood · doi:10.1182/blood.2020009655 · Cited by 119
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Bielski, C. M., Donoghue, M. T. A., Gadiya, M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A., Harris, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.003 · Cited by 106
“To ensure our classification of driver and passenger (or VUS) mutations in oncogenes did not inadvertently misclassify true driver mutations as VUSs, as would be predicted by recent saturation analyses of driver mutations in cancer (Chang et al., 2018; Lawrence et al., 2014), we expressed nine MAP2K1 (MEK1) variants o…”
BackgroundProteomics in Cancer Biomarkers Discovery: Challenges and Applications
Sallam, R. M. (2015) · Disease Markers · doi:10.1155/2015/321370 · Cited by 111
“While several genes were identified by genomics technologies to be specifically related to cancers [2], the function of such genes and the data interpretation in the context of functional networks require the power of proteomics.”
BackgroundNetSig: network-based discovery from cancer genomes
Horn, H., Lawrence, M. S., Chouinard, C. R., Shrestha, Y., Hu, J. X., Worstell, E., Shea, E., Ilic, N., Kim, E., Kamburov, A., et al. (2018) · Nature Methods · doi:10.1038/nmeth.4514 · Cited by 105
Self-citationAn epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 109
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Cheng, J., Demeulemeester, J., Wedge, D. C., Vollan, H. K. M., Pitt, J. J., Russnes, H. G., Pandey, B. P., Nilsen, G., Nord, S., Bignell, G. R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01355-0 · Cited by 105
Wang, G., Chow, R. D.-W., Ye, L., Guzman, C. D., Dai, X., Dong, M. B., Zhang, F., Sharp, P. A., Platt, R. J., & Chen, S. (2018) · Science Advances · doi:10.1126/sciadv.aao5508 · Cited by 103
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodríguez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 123
“…impact, and population allele frequency; (2) relevance in cancer estimated by Cancer Gene Census (CGC) of COSMIC v84 [30], TumorPortal resource [31], Tamborero et al. [32], and OncoScape [33]; (3) essentiality from RNA interference (RNAi) experiments in cancer cell lines from Achilles project…”
BackgroundResultTherapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
Mondal, G., Stevers, M., Goode, B., Ashworth, A., & Solomon, D. A. (2019) · Nature Communications · doi:10.1038/s41467-019-09659-z · Cited by 124
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
Bennett, R. L., Bele, A., Small, E. C., Will, C., Nabet, B., Oyer, J. A., Huang, X., Ghosh, R. P., Grzybowski, A. T., Yu, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0393 · Cited by 107
Liu, H., Qiu, C., Wang, B., Bing, P., Tian, G., Zhang, X., Ma, J., He, B., & Yang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.619330 · Cited by 107
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 115
Genome-wide analysis of somatic noncoding mutation patterns in cancer
Dietlein, F., Wang, A. B., Fagre, C. R., Tang, A., Besselink, N. J. M., Cuppen, E. P. J. G., Li, C., Sunyaev, S. R., Neal, J. T., & Allen, E. M. V. (2022) · Science · doi:10.1126/science.abg5601 · Cited by 123
Unraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 108
Self-citationPrecision autophagy directed by receptor regulators – emerging examples within the TRIM family
Kimura, T., Mandell, M., & Deretic, V. (2016) · Journal of Cell Science · doi:10.1242/jcs.163758 · Cited by 104
“A recent sequencing of tumor tissues has revealed that TRIM23 is a previously unappreciated gene involved in cancer progression (Lawrence et al., 2014).”
BackgroundBhanja, P., Mishra, S., Manna, K., Mallick, A., Saha, K. D., & Bhaumik, A. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07343 · Cited by 106
Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
Goldstein, J. T., Berger, A. C., Shih, J., Duke, F. F., Furst, L., Kwiatkowski, D. J., Cherniack, A. D., Meyerson, M. M., & Strathdee, C. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1701 · Cited by 110
Self-citationRepurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Fukumoto, T., Park, P. H., Wu, S., Fatkhutdinov, N., Karakashev, S., Nacarelli, T., Kossenkov, A. V., Speicher, D. W., Jean, S., Zhang, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.019 · Cited by 103
“For example, saturation analysis of The Cancer Genome Atlas (TCGA) cancer mutational profile finds that the ARID1A subunit of the SWI/SNF complex is among the genes that show the highest mutation rates across multiple cancer types (Lawrence et al., 2014).”
Backgroundm6A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression
Zhang, P., He, Q., Lei, Y., Li, Y., Wen, X., Hong, M., Zhang, J., Ren, X., Wang, Y., Yang, X., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1224-3 · Cited by 108
Surdez, D., Zaïdi, S., Grossetête, S., Laud-Duval, K., Ferre, A. S., Mous, L., Vourc’h, T., Tirode, F., Pierron, G., Raynal, V., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.001 · Cited by 112
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S.-C., Kim, S. S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3751 · Cited by 102
“To extensively catalog mutations in these “long-tail” genes 2 will require sequencing thousands of additional specimens from each tumor subset, a daunting challenge for rare malignancies 3 .”
The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process
Wu, C., Wang, H., Ling, S., & Lu, X. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054842 · Cited by 116
SOCS1 regulates senescence and ferroptosis by modulating the expression of p53 target genes
Saint-Germain, E., Mignacca, L., Vernier, M., Bobbala, D., Ilangumaran, S., & Ferbeyre, G. (2017) · Aging · doi:10.18632/aging.101306 · Cited by 102
Correa, B. R., de Araujo, P. R., Qiao, M., Burns, S. C., Chen, C., Schlegel, R., Agarwal, S., Galante, P. A. F., & Penalva, L. O. F. (2016) · Genome Biology · doi:10.1186/s13059-016-0990-4 · Cited by 101
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.